tm logo
RAYLUMI
REGISTERED

on 29 Sep 2020

Last Applicant/ Owned by

PFIZER INC.

66 Hudson Boulevard EastNew York, New York 10001-2192

US

Serial Number

1874482 filed on 21st Dec 2017

Registration Number

TMA1082075 registered on 29th Sep 2020

Registration expiry Date

29th Sep 2030

Correspondent Address

SUITE 300079 WELLINGTON ST. W.BOX 270, TD CENTRETORONTO

ONTARIO

CA

M5K1N2

RAYLUMI

Trademark usage description

pharmaceutical preparations for the prevention and treatment of psychiatric diseases, degenerative nerve diseases and brain disorders, namely, mood, a Read More

Classification Information


Class [005]
Pharmaceutical preparations for the prevention and treatment of psychiatric diseases, degenerative nerve diseases and brain disorders, namely, mood, anxiety and cognitive disorders, Alzheimer's disease, cerebral palsy, Parkinson's disease, Huntington's disease and multiple sclerosis, none of the aforementioned for use in embolization, the treatment of circulatory system conditions or the treatment of tumors and arteriovenous malformations (AVMs); Pharmaceutical preparations for the prevention and treatment of cranial and facial nerve disorders, connective tissue injuries, diseases and disorders, bone and cartilage injuries, diseases and disorders, none of the aforementioned for use in embolization, the treatment of circulatory system conditions or the treatment of tumors and arteriovenous malformations (AVMs); Pharmaceutical preparations for the prevention and treatment of neuromuscular and neurological diseases and disorders, namely, central nervous system diseases and disorders, namely central nervous system infections, brain diseases, central nervous system movement disorders, muscle diseases and disorders, namely inflammatory muscle diseases and disorders and muscular dystrophy, ocular motility and spinal cord infections, injuries and diseases, and seizure disorders, none of the aforementioned for use in embolization, the treatment of circulatory system conditions or the treatment of tumors and arteriovenous malformations (AVMs); Pharmaceutical preparations for the prevention and treatment of genitourinary diseases, namely, inflammatory pelvic, vaginitis, dysmenorrhea, cervix erosion, cervicitis, trachelitis, uterine cervicitis, endomitriosis, sexually transmitted diseases, erectile and sexual dysfunction, infertility and incontinence, none of the aforementioned for use in embolization, the treatment of circulatory system conditions or the treatment of tumors and arteriovenous malformations (AVMs); Pharmaceutical preparations for the prevention and treatment of cardiovascular, gastrointestinal, blood, oncological, ophthalmological and respiratory system diseases and disorders, none of the aforementioned for use in embolization, the treatment of circulatory system conditions or the treatment of tumors and arteriovenous malformations (AVMs); Pharmaceutical preparations for the prevention and treatment of auto-immune diseases and disorders, namely collagen disease, rheumatoid arthritis, systemic lupus erythematosus, alopecia areata, and systemic sclerosis, none of the aforementioned for use in embolization, the treatment of circulatory system conditions or the treatment of tumors and arteriovenous malformations (AVMs); Pharmaceutical preparations for the prevention and treatment of allergies, hypertension, menopause, diabetic neuropathy, arthritis, and pain, none of the aforementioned for use in embolization, the treatment of circulatory system conditions or the treatment of tumors and arteriovenous malformations (AVMs); Antibiotics, anti-infectives, anti-inflammatories, anti-fungals, anti-virals, oral and injectable pharmaceutical contraceptives, human vaccines, none of the aforementioned for use in embolization, the treatment of circulatory system conditions or the treatment of tumors and arteriovenous malformations (AVMs); Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions, none of the aforementioned for use in embolization, the treatment of circulatory system conditions or the treatment of tumors and arteriovenous malformations (AVMs); Pharmaceutical preparations for the prevention and treatment of renal disease and disorders, none of the aforementioned for use in embolization, the treatment of circulatory system conditions or the treatment of tumors and arteriovenous malformations (AVMs); Pharmaceutical preparations for the prevention and treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders, none of the aforementioned for use in embolization, the treatment of circulatory system conditions or the treatment of tumors and arteriovenous malformations (AVMs); Pharmaceutical preparations for the prevention and treatment of muscular atrophy, none of the aforementioned for use in embolization, the treatment of circulatory system conditions or the treatment of tumors and arteriovenous malformations (AVMs); Pharmaceutical preparations for the prevention and treatment of inflammatory diseases, namely inflammatory bowel diseases, inflammatory joint diseases, inflammatory connective tissue diseases, inflammatory muscle diseases and disorders, none of the aforementioned for use in embolization, the treatment of circulatory system conditions or the treatment of tumors and arteriovenous malformations (AVMs); Pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, namely diabetes, hypoglycemia, muscular dystrophy, sickle cell disease, non-alcoholic steatohepatitis and anemia, none of the aforementioned for use in embolization, the treatment of circulatory system conditions or the treatment of tumors and arteriovenous malformations (AVMs); Pharmaceutical preparations for the prevention and treatment of dermatological diseases and conditions, namely eczema, atopic dermatitis, psoriasis, bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, acne, pyoderma, erosion, ulcer, trauma, burned skin, pain and inflammation, none of the aforementioned for use in embolization, the treatment of circulatory system conditions or the treatment of tumors and arteriovenous malformations (AVMs).


Classification kind code

11

Mark Details


Serial Number

1874482

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 42
on 15th Jan 2020
Advertised
Submitted for opposition 26
on 02th Dec 2019
Approved
Submitted for opposition 27
on 02th Dec 2019
Approval Notice Sent
Submitted for opposition 15
on 18th Oct 2019
Correspondence Created
Submitted for opposition 15
on 26th Jul 2019
Correspondence Created
Submitted for opposition 22
on 27th Mar 2019
Search Recorded
Submitted for opposition 20
on 27th Mar 2019
Examiner's First Report
Submitted for opposition 31
on 27th Dec 2017
Formalized
Submitted for opposition 1
on 22nd Dec 2017
Created
Submitted for opposition 30
on 21st Dec 2017
Filed